Galderma’s Restylane Volyme study hits 94.4% response rate in China

Galderma Group AG (SIX: GALD), the Switzerland-based dermatology company behind Restylane, has reported positive topline data from a randomized Chinese clinical study that could widen the commercial opportunity for its Restylane Volyme hyaluronic acid injectable. The study enrolled 162 adults with moderate-to-severe temple hollowing across six sites in China and compared treatment with Restylane Volyme against a no-treatment control, giving the company local clinical evidence for an additional facial treatment area beyond the product’s existing Chinese mid-face use.

At six months after the last treatment, 94.4% of Restylane Volyme recipients achieved at least a one-grade improvement from baseline in both temples on the Galderma Temple Volume Deficit Scale, compared with just 2.0% of participants in the no-treatment control group. Galderma also reported that responder rates remained high through month 12, while 91.3% of treated patients were assessed by investigators as showing improvement in both temples on the Global Aesthetic Improvement Scale at the 12-month point. No treatment-related serious adverse events or granulomas were reported in the topline findings.

The significance for Galderma is broader than another favorable clinical dataset. Restylane Volyme was launched in China in May 2024 for correction of mid-face volume deficit and contour deficiency, meaning the latest study is not announcing the initial arrival of the product in China. Instead, it gives Galderma evidence supporting its ambition to extend the range of conditions and facial areas for which Chinese practitioners and patients may eventually be able to use the injectable, subject to the applicable regulatory process.

What did the Restylane Volyme China temple hollowing study actually show?

The study, identified as NCT06665477 and sponsored by Galderma R&D, was designed as a randomized, no-treatment-controlled, evaluator-blinded multicenter investigation. Participants were Chinese adults aged 18 or older with moderate or severe temple hollowing in both temples, and the study randomized patients between Restylane Volyme treatment and a control group. The registered primary endpoint assessed the proportion of participants achieving at least a one-grade improvement in both temples six months after the last treatment, as determined by a blinded evaluator.

Galderma said the trial divided 162 participants in a 2:1 ratio between Restylane Volyme treatment and no treatment. Beyond the 94.4% primary responder rate, patient-reported measures provided another commercially relevant signal: more than 84% of participants remained satisfied with both the natural appearance and natural feel of their temples through month 12, more than 90% said they would recommend the treatment to a friend, and more than 86% said they would undergo the treatment again. Half of the participants also reported feeling comfortable returning to social activities within 24 hours of their initial treatment.

The safety findings are particularly relevant because temple augmentation involves an anatomically complex facial area where clinicians must consider injection technique as well as product characteristics. Galderma reported no treatment-related serious adverse events and no granulomas in the study. The company describes Restylane Volyme as a moderately soft and flexible gel produced using its OBT technology and said a dual-layer technique involving both needle and cannula can be used to position the product according to individual treatment requirements.

There is, however, an important distinction between positive topline results and a completed regulatory expansion. The detailed results cited by Galderma remain company data on file in the September 16 announcement, and the company did not disclose a Chinese regulatory filing date, approval timetable or expected launch date for a temple hollowing indication. Full publication or presentation of the dataset, along with any subsequent regulatory action in China, will therefore be important milestones for assessing how quickly the clinical result could translate into incremental commercial activity.

Why is Galderma targeting temple hollowing in China?

Temple volume can decline with aging, altering facial contours and producing a more hollow appearance around the upper face. Galderma also linked growing attention to this area with facial volume changes associated with medication-driven weight loss, although the commercial opportunity extends to the wider aesthetic-rejuvenation population rather than a single patient group. According to the company, Chinese patients currently have relatively limited treatment options for temple hollowing, giving differentiated products with locally generated evidence an opportunity to address an underserved treatment area.

China has been part of Galderma’s broader expansion strategy for injectable aesthetics for several years. When Restylane Volyme entered the Chinese market in 2024, Galderma said the country’s aesthetic-medicine market had grown faster than the global market during the preceding decade while penetration remained comparatively low. The company also identified hyaluronic acid fillers as one of the most widely sold aesthetic product categories in China, making additional approved indications potentially valuable because they allow an existing brand and practitioner network to address more facial treatment areas.

The approach also illustrates an important part of the economics of mature aesthetics platforms. A manufacturer does not necessarily need an entirely new injectable for every new commercial opportunity; generating evidence and obtaining additional indications for products already supported by manufacturing, physician education and established brand recognition can broaden the addressable market. For Restylane Volyme, the latest Chinese study therefore matters not only because of its efficacy numbers but because it could extend the commercial life and clinical versatility of an established asset.

How does the China study connect with Restylane Contour in the United States?

Restylane Volyme is marketed as Restylane Contour in the United States, where the regulatory pathway for temple hollowing has already moved further ahead. The United States Food and Drug Administration approved Restylane Contour for correction of temple hollowing in March 2026 for patients over the age of 21, expanding its previous uses for cheek augmentation and correction of mid-face contour deficiencies. Galderma said the United States approval was supported by clinical evidence showing results lasting for as long as 18 months.

That geographical sequencing matters because it demonstrates Galderma’s broader lifecycle-management strategy for the Restylane franchise. Different markets can have different approved indications and regulatory requirements, meaning clinical programs tailored to local populations can support gradual expansion of the same product platform across treatment areas and countries. The Chinese study adds population-specific data rather than simply relying on evidence generated elsewhere, potentially strengthening the case for local regulatory and physician acceptance.

Galderma has continued to add products, indications and delivery technologies across its injectable portfolio. During the first half of 2026, the company said it rolled out the Restylane SkinBoosters SmartClick syringe in China while continuing the scaling of Sculptra in the country. These moves show that China is being addressed as part of a broader aesthetics portfolio strategy rather than through Restylane Volyme alone.

Why could another Restylane indication matter financially for Galderma?

Injectable Aesthetics remains a major business for Galderma Group AG. In the first half of 2026, the category generated net sales of $1.437 billion, up 12.1% year over year at constant currency, while the Fillers & Biostimulators subcategory produced $611 million of sales, representing constant-currency growth of 10.5%. Galderma said that growth was achieved despite continued softness in the broader fillers market and that it gained market share in both the United States and international markets.

That backdrop makes indication expansion strategically useful. A softer overall filler market raises the importance of differentiated products, new anatomical uses, geographic expansion and stronger clinical evidence as companies compete for physician and patient spending. A temple hollowing indication in China, if ultimately obtained and successfully commercialized, would give Galderma another avenue for driving utilization of an existing Restylane product without requiring the commercial build-out associated with an entirely new franchise.

Investors should not, however, treat the 162-patient study as a material revenue event on its own. Galderma has not disclosed expected sales from a potential Chinese temple hollowing indication, a regulatory decision timetable or pricing assumptions for that use. Its financial significance is therefore better viewed as part of a cumulative lifecycle strategy in which multiple product launches, indication expansions and geographic approvals can collectively support the growth of the Injectable Aesthetics franchise.

The broader company is currently growing considerably faster than the fillers operation alone. Galderma generated first-half 2026 net sales of $3.134 billion, up 24.6% at constant currency, while core EBITDA reached $802 million and the core EBITDA margin rose to 25.6%. Following the first-half performance, Galderma lifted its full-year 2026 constant-currency sales-growth guidance to 19% to 21% from the previous 17% to 20% range.

What does Galderma’s recent share price say about investor sentiment?

Galderma Group AG shares closed at CHF153.30 on September 15, 2026, down 1.48% for the session, immediately before the Restylane Volyme China study announcement. The shares had closed at CHF167.90 on August 31 and have traded within a 52-week range of CHF130.20 to CHF188.25, indicating that recent price action has been weaker than the company’s underlying first-half revenue growth might suggest.

Because Galderma released the Restylane Volyme results before the September 16 Swiss trading session, the September 15 closing price cannot be interpreted as a market reaction to the new data. The next trading sessions will provide a cleaner indication of whether investors assign measurable value to the development, although a single indication-expansion study is unlikely to outweigh broader drivers such as earnings expectations, therapeutic dermatology growth, injectable-aesthetics demand, regulatory developments and valuation.

Sentiment around Galderma therefore has two distinct layers. Operational performance remains strong, with double-digit growth across its principal product categories, higher 2026 sales guidance and continuing international expansion, while the recent share-price retreat shows that strong business execution does not automatically translate into uninterrupted equity gains. The Restylane Volyme result adds another favorable clinical datapoint, but the commercial impact will depend on whether Galderma turns the evidence into regulatory expansion and meaningful utilization in China.

What should investors and the aesthetics market watch next?

The next decisive development will be regulatory rather than clinical headline generation. Galderma has established that Restylane Volyme met the study’s primary endpoint in Chinese patients, but it has not yet announced that Chinese regulators have approved the product specifically for temple hollowing. Confirmation of a regulatory submission, acceptance for review or eventual approval would move the story from evidence generation toward a tangible commercial expansion.

Fuller disclosure of the trial results will also matter. Published or congress-presented data could provide more granular information on treatment volumes, repeat injections, adverse events, subgroup outcomes and the durability of correction beyond the headline responder rates. Those details would allow physicians and investors to compare Restylane Volyme more closely with competing hyaluronic acid fillers and other injectable approaches to temporal volume restoration.

For Galderma Group AG, the larger strategic question is whether portfolio expansion can keep Fillers & Biostimulators growing despite a softer overall filler market. The 94.4% six-month response rate in China gives Restylane Volyme a strong clinical headline, while high patient satisfaction and sustained results through 12 months strengthen the product’s positioning. Converting that evidence into regulatory clearance, practitioner adoption and incremental sales will determine how much the Chinese study ultimately contributes to Galderma’s injectable aesthetics growth story.